Royal Philips Electronics and Definiens have signed a memorandum of understanding to jointly develop and market clinical decision support solutions for digital pathology.
Leveraging its expertise in medical imaging and healthcare informatics solutions (radiology Picture Archiving and Communications Systems), Philips is committed to delivering highly integrated solutions for digital pathology.
Accurate and robust image-analysis applications for quantifying biomarkers and histological features in tissue samples are an essential element of such solutions.
The initial project between Philips and Definiens will focus on immunohistology-based breast cancer diagnostics, which includes the detection of biomarkers HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), Ki67 and p53.
Philips and Definiens also plan to investigate solutions for other cancers, such as prostate and colon cancer.
